Naperville, IL -- (SBWIRE) -- 12/02/2013 -- Reportstack, provider of premium market research reports announces the addition of Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022 market report to its offering
The publisher has released its new Country report, “HCV - UK Drug Forecast and Market Analysis to 2022”. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. The publisher expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.
The anticipated drivers of growth in the UK market included increased awareness of HCV, the launch of improved HCV regimens, and advocacy for access to next-generation therapies.
Janssen’s Incivo is the current market leader in the UK. Incivo was among the first DAA HCV therapies launched in the UK. The regimen had an improved efficacy compared with the previous standard of care for HCV GT1, a combination of peginterferon and ribavirin. The publisher assumes that Incivo’s shorter duration of triple-therapy (i.e., DAA, peginterferon, and ribavirin) compared with Merck’s Victrelis enabled it to outcompete Victrelis for market share. Incivo and Victrelis are both associated with adverse events, which has resulted in HCV-infected patients in the UK deciding to forego therapy in order to await the launch of more-tolerable HCV therapies.
Scope
Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the UK from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the UK HCV market.
Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for HCV
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in the UK
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/146804/hepatitis-c-virus-united-kingdom-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###